BD Announces Results for Fourth Fiscal Quarter and Full Year



    
    - Reports record revenues for the quarter and year

    - Fourth-quarter earnings per share from continuing operations increased
    15% to 98 cents

    - Full-year earnings per share from continuing operations, excluding
    specified items, increased 15% to $3.84

    - Expects full fiscal year 2008 earnings per share from continuing
    operations, excluding specified items, to increase 10%-12%
    

    FRANKLIN LAKES, N.J., Nov. 1 /CNW/ -- BD (Becton, Dickinson and Company)
(NYSE:   BDX) today reported record quarterly revenues of $1.651 billion for the
fourth fiscal quarter ended September 30, 2007, representing an increase of 13
percent over the prior year period.  This quarter's growth rate reflects the
favorable impact on all segments from foreign currency translation, which
overall is estimated to account for 3 percentage points of the increase in
quarterly revenues.
    For the full fiscal year ended September 30, 2007, BD reported record
revenues of $6.360 billion, representing an increase of 11 percent over the
prior year, which reflects an overall estimated 3 percent favorable impact
from foreign currency translation that affected all segments.
    "We are pleased with our solid finish to another successful year during
which BD exceeded its financial and operating goals," said Edward J. Ludwig,
Chairman, President and Chief Executive Officer.  "Our performance was strong
across all three segments.  We continue to invest in innovation while
delivering double-digit earnings growth.  Strong cash flow driven by operating
margin expansion enables us to return value to shareholders through dividend
increases and share repurchases.  We are enthusiastic about our outlook for
fiscal 2008."
    Fourth Quarter Earnings and Analysis of Full Fiscal Year 2007 and 2006
Earnings
    Reported diluted earnings per share from continuing operations of 98
cents for the fourth quarter increased by 15 percent over diluted earnings per
share from continuing operations of 85 cents for the fourth fiscal quarter of
2006.
    For the twelve-month period ending September 30, 2007, reported diluted
earnings per share were $3.36. The following analysis (Table 1) of diluted
earnings per share from continuing operations for the twelve-month periods
ended September 30, 2007 and 2006 identifies specified items that affect the
comparability of results between periods.  As illustrated, diluted earnings
per share from continuing operations, excluding specified items, of $3.84 for
fiscal 2007 increased by 15 percent over diluted earnings per share from
continuing operations, excluding specified items, of $3.34 for fiscal 2006.


    (Table 1)

    
                                                     Twelve Months Ended
                                                         September 30,
    

    FY2007   FY2006    % Change

    Diluted EPS from Continuing Operations:        $ 3.36   $ 3.18         6%

    
    Specified Items:
     In-Process Research and Development Charge(1)   0.48     0.21
     Insurance Settlement(2)                            -    (0.04)
     Rounding                                           -    (0.01)
                                                     0.48     0.16
    

    
    Diluted EPS from Continuing Operations
    Excluding Specified Items:                     $ 3.84   $ 3.34        15%
    

    
     (1) Represents the effect on diluted earnings per share from continuing
         operations of the in-process research and development ("IPR&D")
         charges recorded in fiscal 2007 primarily related to the TriPath
         acquisition, and in fiscal 2006 related to the GeneOhm acquisition.
     (2) Represents the effect on diluted earnings per share from continuing
         operations in fiscal 2006 related to proceeds received from insurance
         settlements associated with the Company's previously owned latex
         glove business.
    Segment Results
    
    In the BD Medical segment, worldwide revenues for the quarter were $868
million, representing an increase of 11 percent from the prior year period.
For the full fiscal year ended September 30, 2007, the BD Medical segment
reported 10 percent revenue growth to $3.421 billion.  Strong sales in the
Pharmaceutical Systems unit continued to significantly contribute to the
growth of the segment.
    In the BD Diagnostics segment, worldwide revenues for the quarter were
$498 million, representing an increase of 16 percent from the prior year's
quarter.  This growth includes $29 million of revenues from TriPath, a maker
of innovative solutions to improve the clinical management of cancer, which
was acquired at the end of the first quarter of fiscal 2007.  For the full
fiscal year ended September 30, 2007, the BD Diagnostics segment reported
revenue growth of 11 percent to $1.905 billion, which includes $88 million of
revenues from TriPath.
    In the BD Biosciences segment, worldwide revenues for the quarter were
$285 million, representing an increase of 14 percent from the prior year
period.  Sales of flow cytometry and bioimaging instruments, flow cytometry
reagents, and advanced bioprocessing products contributed to growth.  For the
full fiscal year ended September 30, 2007, the BD Biosciences segment reported
13 percent revenue growth to $1.034 billion, resulting from continued strong
sales of those same products.
    
    Geographic Results
    
    Fourth quarter revenues in the U.S. were $790 million, representing an
increase of 12 percent over the prior year period.  Revenues outside the U.S.
were $861 million, representing an increase of 13 percent over the prior year
period, and reflected an estimated 5 percent favorable impact from foreign
currency translation.
    For the full fiscal year ended September 30, 2007, revenues in the U.S.
were $3.033 billion, representing an increase of 11 percent over the prior
year period.  Revenues outside of the U.S. were $3.327 billion, representing
an increase of 11 percent over the prior year period, and reflected an
estimated 5 percent favorable impact from foreign currency translation.
    
    Fiscal 2008 Outlook for Full Year
    
    The Company estimates that diluted earnings per share from continuing
operations for the full fiscal year 2008 will increase approximately 10 to 12
percent over diluted earnings per share from continuing operations, excluding
specified items, of $3.84 for the fiscal year 2007.
    
    Conference Call Information
    
    A conference call regarding BD's fourth fiscal quarter and full year
results and its expectations for fiscal year 2008 will be broadcast live on
BD's website, www.bd.com/investors, at 10:00 a.m. (ET) Thursday, November 1,
2007.  The conference call will be available for replay through the close of
business on November 8, 2007 on BD's website, www.bd.com/investors, or at 1-
800-475-6701 (domestic) and 1-320-365-3844 (international), access code
889224.
    This news release contains certain non-GAAP financial measures.  A
reconciliation of these and other measures to the comparable GAAP measures is
included in this release and in the attached financial tables.
    
    About BD
    
    BD, a leading global medical technology company that manufactures and
sells medical devices, instrument systems and reagents, is dedicated to
improving people's health throughout the world.  BD is focused on improving
drug therapy, enhancing the quality and speed of diagnosing infectious
diseases, and advancing research and discovery of new drugs and vaccines.  The
Company's capabilities are instrumental in combating many of the world's most
pressing diseases.  Founded in 1897 and headquartered in Franklin Lakes, New
Jersey, BD employs approximately 28,000 people in approximately 50 countries
throughout the world.  The Company serves healthcare institutions, life
science researchers, clinical laboratories, industry and the general public.
For more information, please visit www.bd.com.
    This press release, including the section entitled "Fiscal 2008 Outlook
for Full Year," contains certain estimates and other forward-looking
statements (as defined under Federal securities laws) regarding BD's
performance, including future revenues, earnings per share and income, or
events or developments that BD expects to occur or anticipates occurring in
the future.  All such statements are based upon current expectations of BD and
involve a number of business risks and uncertainties.  Actual results could
vary materially from anticipated results described, implied or projected in
any forward-looking statement.  With respect to forward-looking statements
contained herein, factors that could cause actual results to vary materially
from any forward-looking statement include, but are not limited to:
competitive factors; pricing and market share pressures; changes in interest
or foreign currency exchange rates; difficulties inherent in product
development and delays in product introductions; changes in regional, national
or foreign economic conditions; further increases in energy costs and their
effect on, among other things, the cost of producing BD's products;
fluctuations in costs and availability of raw materials and in BD's ability to
maintain favorable supplier arrangements and relationships; uncertainties of
litigation (as described in BD's filings with the Securities and Exchange
Commission); the effects of potential pandemic diseases; changes in healthcare
or other governmental regulation; and issuance of new or revised accounting
standards, as well as other factors discussed in this press release and in
BD's filings with the Securities and Exchange Commission.  We do not intend to
update any forward-looking statements to reflect events or circumstances after
the date hereof except as required by applicable laws or regulations.



    
    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per-share data)
    

    
                                        Three Months Ended September 30,
                                           2007         2006    % Change
    

    REVENUES                          $ 1,651,101  $ 1,462,616    12.9

    
    Cost of products sold                 807,377      709,038    13.9
    Selling and administrative            399,525      378,252     5.6
    Research and development              100,430       82,399    21.9
    TOTAL OPERATING COSTS
     AND EXPENSES                       1,307,332    1,169,689    11.8
    

    OPERATING INCOME                      343,769      292,927    17.4

    
    Interest expense                      (10,268)     (14,056)  (26.9)
    Interest income                         9,083       15,488   (41.4)
    Other expense, net                     (4,334)      (4,763)   (9.0)
    

    
    INCOME FROM CONTINUING
     OPERATIONS BEFORE INCOME
     TAXES                                338,250      289,596    16.8
    

    Income tax provision                   89,142       72,716    22.6

    
    INCOME FROM CONTINUING
     OPERATIONS                           249,108      216,880    14.9
    

    
    INCOME/(LOSS) FROM DISCONTINUED
     OPERATIONS NET OF INCOME TAX
     PROVISION/(BENEFIT) OF $1,176
     AND $(20,695), RESPECTIVELY            1,923      (42,901)     NM
    

    NET INCOME                        $   251,031  $   173,979    44.3

    EARNINGS PER SHARE

    
    Basic:
    Income from continuing
     operations                       $      1.02  $      0.88    15.9
    Income/(loss) from discontinued
     operations                       $      0.01  $     (0.17)     NM
    Net income                        $      1.03  $      0.71    45.1
    

    
    Diluted:
    Income from continuing
     operations                       $      0.98  $      0.85    15.3
    Income/(loss) from discontinued
     operations                       $      0.01  $     (0.17)     NM
    Net income                        $      0.99  $      0.68    45.6
    

    AVERAGE SHARES OUTSTANDING

    
         Basic                            243,841      245,522
         Diluted                          253,009      254,843
    

    NM - Not Meaningful



    
    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per-share data)
    

    
                                        Twelve Months Ended September 30,
                                          2007         2006    % Change
    

    REVENUES                          $ 6,359,708  $ 5,738,017    10.8

    
    Cost of products sold               3,071,921    2,793,265    10.0
    Selling and administrative          1,602,404    1,448,166    10.7
    Research and development              360,050      301,872    19.3
    Acquired in-process research and
     development                          122,133       53,300      NM
    TOTAL OPERATING COSTS AND
     EXPENSES                           5,156,508    4,596,603    12.2
    

    OPERATING INCOME                    1,203,200    1,141,414     5.4

    
    Interest expense                      (46,420)     (66,046)  (29.7)
    Interest income                        46,221       59,296   (22.1)
    Other expense, net                        944       (8,762)     NM
    

    
    INCOME FROM CONTINUING
     OPERATIONS BEFORE INCOME
     TAXES                              1,203,945    1,125,902     6.9
    

    Income tax provision                  347,778      310,792    11.9

    
    INCOME FROM CONTINUING
     OPERATIONS                           856,167      815,110     5.0
    

    
    INCOME (LOSS) FROM DISCONTINUED
     OPERATIONS NET OF INCOME TAX
     PROVISION/(BENEFIT) OF $15,242
     AND $(32,823), RESPECTIVELY           25,085      (62,830)     NM
    

    NET INCOME                        $   881,252  $   752,280    17.1

    EARNINGS PER SHARE

    
    Basic:
    Income from continuing
     operations                       $      3.50  $      3.30     6.1
    Income (loss) from discontinued
     operations                       $      0.10  $     (0.25)     NM
    Net income (1)                    $      3.60  $      3.04    18.4
    

    
    Diluted:
    Income from continuing
     operations                       $      3.36  $      3.18     5.7
    Income (loss) from discontinued
     operations                       $      0.10  $     (0.24)     NM
    Net income (1)                    $      3.46  $      2.93    18.1
    

    AVERAGE SHARES OUTSTANDING

    
         Basic                            244,929      247,067
         Diluted                          254,810      256,554
    

    NM - Not Meaningful

    (1) Total per share amounts may not add due to rounding.



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Twelve Months Ended September 30,
    (Unaudited; Amounts in thousands, except per-share data)
    

    
                                                 2007
                                  As       TriPath     Plasso    Excluding
                               Reported    IPR&D (1)   IPR&D (1)   Items
    

    
    Operating Income         $ 1,203,200  $ 114,739  $  7,394   $ 1,325,333
        as a % of revenues          18.9%                              20.8%
    

    
    Income taxes                 347,778          -         -       347,778
        effective tax rate          28.9%         -         -          26.2%
    

    
    Income from continuing
     operations                  856,167    114,739     7,394       978,300
        as a % of revenues          13.5%                              15.4%
    

    
    Diluted earnings per
     share
    Income from continuing
     operations              $      3.36  $    0.45  $   0.03    $     3.84
    


    
    (1) Represents the acquired in-process research and development charges of
    $114,739 and $7,394 related to the TriPath and Plasso acquisitions,
    respectively.
    



    
                                                2006
                                  As     Insurance   GeneOhm
                               Reported  Settlement   IPR&D     Excluding
                                            (1)        (2)        Items
    

    
    Selling and
     administrative          $ 1,448,166   $ 17,000   $   -     $ 1,465,166
       as a % of revenues           25.2%                              25.5%
    

    
    Operating Income           1,141,414    (17,000)   53,300     1,177,714
       as a % of revenues           19.9%                              20.5%
    

    
    Income taxes                 310,792     (6,460)      -         304,332
       effective tax rate           27.6%                              26.2%
    

    
    Income from continuing
     operations                  815,110    (10,540)   53,300       857,870
       as a % of revenues           14.2%                              15.0%
    

    
    Diluted earnings per
     share
    Income from continuing
     operations  (3)         $      3.18   $  (0.04)  $  0.21     $    3.34
    


    
    (1) Represents the effect in 2006 related to proceeds received from
    insurance settlements in connection with the Company's previously owned
    latex glove business.
    

    
    (2) Represents the acquired in-process research and development charge of
    $53,300 related to the GeneOhm acquisition.
    

    (3) Total per share amounts may not add due to rounding.



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)
    

    
                                         Three Months Ended September 30,
                                           2007         2006   % Change
    

    
    BD MEDICAL
       United States                   $   392,166  $   361,198    8.6
       International                       476,128      422,616   12.7
    TOTAL                              $   868,294  $   783,814   10.8
    

    
    BD DIAGNOSTICS
       United States                   $   272,743  $   232,343   17.4
       International                       225,206      196,523   14.6
    TOTAL                              $   497,949  $   428,866   16.1
    

    
    BD BIOSCIENCES
       United States                   $   125,367  $   110,319   13.6
       International                       159,491      139,617   14.2
    TOTAL                              $   284,858  $   249,936   14.0
    

    
    TOTAL REVENUES
       United States                   $   790,276  $   703,860   12.3
       International                       860,825      758,756   13.5
    TOTAL                              $ 1,651,101  $ 1,462,616   12.9
    



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)
    

    
                                        Twelve Months Ended September 30,
                                         2007         2006     % Change
    

    
    BD MEDICAL
       United States                   $ 1,538,308  $ 1,418,077    8.5
       International                     1,882,362    1,688,569   11.5
    TOTAL                              $ 3,420,670  $ 3,106,646   10.1
    

    
    BD DIAGNOSTICS
       United States                   $ 1,054,388  $   919,071   14.7
       International                       850,717      796,019    6.9
    TOTAL                              $ 1,905,105  $ 1,715,090   11.1
    

    
    BD BIOSCIENCES
       United States                   $   440,309  $   402,196    9.5
       International                       593,624      514,085   15.5
    TOTAL                              $ 1,033,933  $   916,281   12.8
    

    
    TOTAL REVENUES
       United States                   $ 3,033,005  $ 2,739,344   10.7
       International                     3,326,703    2,998,673   10.9
    TOTAL                              $ 6,359,708  $ 5,738,017   10.8
    



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30,
    (Unaudited; Amounts in thousands)
    

    
                                                  United States
                                            2007       2006   % Change
    

    
    BD MEDICAL
       Medical Surgical Systems         $   243,427  $ 231,932    5.0
       Diabetes Care                         98,384     90,789    8.4
       Pharmaceutical Systems                44,376     32,856   35.1
       Ophthalmic Systems                     5,979      5,621    6.4
    TOTAL                               $   392,166  $ 361,198    8.6
    

    
    BD DIAGNOSTICS
       Preanalytical Systems            $   138,203  $ 131,838    4.8
       Diagnostic Systems                   134,540    100,505   33.9
    TOTAL                               $   272,743  $ 232,343   17.4
    

    
    BD BIOSCIENCES
       Discovery Labware                $    40,234  $  37,377    7.6
       Immunocytometry Systems               64,232     52,679   21.9
       Pharmingen                            20,901     20,263    3.1
    TOTAL                               $   125,367  $ 110,319   13.6
    

    TOTAL UNITED STATES                 $   790,276  $ 703,860   12.3



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)
    

    
                                                 International
                                                              % Change
                                                     -------------------------
                                                                 FX       FX
                                    2007      2006   Reported  Neutral  Impact
    

    
    BD MEDICAL
       Medical Surgical Systems   $ 233,366 $ 215,951     8.1     2.0    6.1
       Diabetes Care                 82,851    75,337    10.0     4.5    5.5
       Pharmaceutical Systems       149,023   121,886    22.3    15.9    6.4
       Ophthalmic Systems            10,888     9,442    15.3     8.9    6.4
    TOTAL                         $ 476,128 $ 422,616    12.7     6.6    6.1
    

    
    BD DIAGNOSTICS
       Preanalytical Systems      $ 122,337 $ 107,399    13.9     7.5    6.4
       Diagnostic Systems           102,869    89,124    15.4    10.3    5.1
    TOTAL                         $ 225,206 $ 196,523    14.6     8.8    5.8
    

    
    BD BIOSCIENCES
       Discovery Labware          $  32,976 $  30,601     7.8     3.1    4.7
       Immunocytometry Systems      105,403    89,768    17.4    12.6    4.8
       Pharmingen                    21,112    19,248     9.7     4.6    5.1
    TOTAL                         $ 159,491 $ 139,617    14.2     9.4    4.8
    

    TOTAL INTERNATIONAL           $ 860,825 $ 758,756    13.5     7.7    5.8



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)
    

    
                                                    Total
                                                             % Change
                                                     -------------------------
                                                                 FX       FX
                                    2007      2006   Reported  Neutral  Impact
    

    
    BD MEDICAL
       Medical Surgical Systems   $  476,793  $   447,883   6.5    3.5     3.0
       Diabetes Care                 181,235      166,126   9.1    6.6     2.5
       Pharmaceutical Systems        193,399      154,742  25.0   20.0     5.0
       Ophthalmic Systems             16,867       15,063  12.0    7.9     4.1
    TOTAL                        $   868,294      783,814  10.8    7.5     3.3
    

    
    BD DIAGNOSTICS
       Preanalytical Systems     $   260,540  $   239,237   8.9    6.0     2.9
       Diagnostic Systems            237,409      189,629  25.2   22.8     2.4
    TOTAL                        $   497,949      428,866  16.1   13.4     2.7
    

    
    BD BIOSCIENCES
       Discovery Labware         $    73,210  $    67,978   7.7    5.6     2.1
       Immunocytometry Systems       169,635      142,447  19.1   16.0     3.1
       Pharmingen                     42,013       39,511   6.3    3.8     2.5
    TOTAL                        $   284,858      249,936  14.0   11.3     2.7
    

    TOTAL REVENUES               $ 1,651,101  $ 1,462,616  12.9    9.9    
3.0



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30,
    (Unaudited; Amounts in thousands)
    

    
                                         United States
                                2007          2006     % Change
    

    
    BD MEDICAL
       Medical Surgical
        Systems             $   954,971   $   904,371     5.6
       Diabetes Care            378,639       363,298     4.2
       Pharmaceutical
        Systems                 180,337       127,896    41.0
       Ophthalmic Systems        24,361        22,512     8.2
    TOTAL                   $ 1,538,308   $ 1,418,077     8.5
    

    
    BD DIAGNOSTICS
       Preanalytical
        Systems             $   541,415   $   511,948     5.8
       Diagnostic Systems       512,973       407,123    26.0
    TOTAL                   $ 1,054,388   $   919,071    14.7
    

    
    BD BIOSCIENCES
       Discovery Labware    $   149,939   $   138,205     8.5
       Immunocytometry
        Systems                 210,916       186,369    13.2
       Pharmingen                79,454        77,622     2.4
    TOTAL                   $   440,309   $   402,196     9.5
    

    TOTAL UNITED STATES     $ 3,033,005   $ 2,739,344    10.7



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)
    

    
                                               International
                                                            % Change
                                                    -------------------------
                                                                FX       FX
                                2007         2006   Reported  Neutral  Impact
    

    
    BD MEDICAL
       Medical Surgical
        Systems             $   909,109  $   844,372    7.7     2.8     4.9
       Diabetes Care            317,342      293,235    8.2     3.3     4.9
       Pharmaceutical
        Systems                 611,563      511,798   19.5    12.5     7.0
       Ophthalmic Systems        44,348       39,164   13.2     6.7     6.5
    TOTAL                   $ 1,882,362  $ 1,688,569   11.5     5.9     5.6
    

    
    BD DIAGNOSTICS
       Preanalytical
        Systems             $   465,276  $   415,811   11.9     6.2     5.7
       Diagnostic Systems       385,441      380,208    1.4    (2.5)    3.9
    TOTAL                   $   850,717  $   796,019    6.9     2.0     4.9
    

    
    BD BIOSCIENCES
       Discovery Labware    $   127,963  $   117,880    8.6     4.4     4.2
       Immunocytometry
        Systems                 377,485      316,478   19.3    14.2     5.1
       Pharmingen                88,176       79,727   10.6     5.8     4.8
    TOTAL                   $   593,624  $   514,085   15.5    10.7     4.8
    

    TOTAL INTERNATIONAL     $ 3,326,703  $ 2,998,673   10.9     5.7     5.2



    
    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Twelve Months Ended September 30, (continued)
    (Unaudited; Amounts in thousands)
    

    
                                                  Total
                                                              % Change
                                                     -------------------------
                                                                 FX       FX
                                2007         2006    Reported  Neutral  Impact
    

    
    BD MEDICAL
       Medical Surgical
        Systems             $ 1,864,080   $ 1,748,743    6.6     4.2     2.4
       Diabetes Care            695,981       656,533    6.0     3.8     2.2
       Pharmaceutical
        Systems                 791,900       639,694   23.8    18.2     5.6
       Ophthalmic Systems        68,709        61,676   11.4     7.3     4.1
    TOTAL                   $ 3,420,670   $ 3,106,646   10.1     7.1     3.0
    

    
    BD DIAGNOSTICS
       Preanalytical
        Systems             $ 1,006,691   $   927,759    8.5     5.9     2.6
       Diagnostic Systems       898,414       787,331   14.1    12.2     1.9
    TOTAL                   $ 1,905,105   $ 1,715,090   11.1     8.8     2.3
    

    
    BD BIOSCIENCES
       Discovery Labware    $   277,902   $   256,085    8.5     6.6     1.9
       Immunocytometry
        Systems                 588,401       502,847   17.0    13.8     3.2
       Pharmingen               167,630       157,349    6.5     4.1     2.4
    TOTAL                   $ 1,033,933   $   916,281   12.8    10.1     2.7
    

    TOTAL REVENUES          $ 6,359,708   $ 5,738,017   10.8     8.1     2.7




For further information:

For further information: Patricia A. Spinella, Investor Relations, 
+1-201-847-5453, or Colleen T. White, Corporate Communications,
+1-201-847-5369,  both for Becton Dickinson and Company Web Site:
http://www.bd.com

Organization Profile

BECTON DICKINSON AND COMPANY

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890